Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: Long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Van Griensven, Johan ^a,b   Phirum, Lay ^a   Choun, Kimcheng ^a   Thai, Sopheak ^a   De Weggheleire, Anja ^b   Lynen, Lutgarde ^b  

^a Sihanouk Hospital Center of HOPE   (Cambodia)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; NEVIRAPINE; BENZOXAZINE DERIVATIVE; LAMIVUDINE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CAMBODIA; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS C; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LONG TERM CARE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; RASH; RETROSPECTIVE STUDY; TIME TO TREATMENT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; COMPLICATION; DRUG EFFECTS; HIV INFECTIONS; KAPLAN MEIER METHOD; LIVER; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; BENZOXAZINES; CAMBODIA; CD4 LYMPHOCYTE COUNT; COINFECTION; FEMALE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; LAMIVUDINE; LIVER; LOGISTIC MODELS; MALE; MIDDLE AGED; NEVIRAPINE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STAVUDINE; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 84895748667     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088552     Document Type: Article

References (61)

1. Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ (2012) HIV-HBV coinfection - a global challenge. N Engl J Med 366: 1749-1752.
2. Ocama P, Seremba E (2011) Management of HIV and hepatitis C virus infections in resource-limited settings. Curr Opin HIV AIDS 6: 539-545.
3. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57: 1333-1342.
4. Global policy report on the prevention and control of viral hepatitis (2013). Word Health Organization; Geneva, Switserland.
5. Dienstag JL (2008) Hepatitis B virus infection. N Engl J Med 359: 1486-1500.
6. Easterbrook P, Sands A, Harmanci H (2012) Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings. Semin Liver Dis 32: 147-157.
7. UNAIDS Report on the global AIDS epidemic (2012). Joint United Nations Programme on HIV/AIDS (UNAIDS); Geneva, Switserland.
8. Hernandez MD, Sherman KE (2011) HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS 6: 478-482.
9. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, et al. (2006) Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 166: 1632-1641. (Pubitemid 44232373)
10. Hoffmann CJ, Thio CL (2007) Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 7: 402-409. (Pubitemid 46765200)
11. Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, et al. (2008) Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 47: 1479-1485.
12. Jones M, Nunez M (2011) HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management. Curr Opin HIV AIDS 6: 546-552.
13. Jain MK (2009) Mortality in patients coinfected with hepatitis B virus and HIV: could antiretroviral therapy make a difference? Clin Infect Dis 48: 1772-1774.
14. Chang CC, Crane M, Zhou J, Mina M, Post JJ, et al. (2013) HIV and co-infections. Immunol Rev 254: 114-142.
15. European AIDS Clinical Society Guidelines. Version 6.1 (2012). European AIDS Clinical Society (EACS).
16. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (2012). Panel on Antiretroviral Guidelines for Adults and Adolescents. Unites States of America, Department of Health and Human Services (DHHS).
17. British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV (2013). British HIV Association.
18. Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, et al. (2004) Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 18: 1169-1177. (Pubitemid 38738516)
19. Than NN, Sungkanuparph S, Maek ANW, Kaewkungwal J, Pitisuttithum P (2012) Comparison of clinical outcomes between HIV-infected patients with and without HCV co-infection in a resource-limited setting. Southeast Asian J Trop Med Public Health 43: 646-651.
20. Tsuchiya N, Pathipvanich P, Rojanawiwat A, Wichukchinda N, Koga I, et al. (2012) Chronic hepatitis B and C co-infection increased all-cause mortality in HAART-naive HIV patients in northern Thailand. Epidemiol Infect: 1-9.
21. Zhou J, Dore GJ, Zhang F, Lim PL, Chen YM (2007) Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol 22: 1510-1518. (Pubitemid 47274591)
22. Lerolle N, Limsreng S, Fournier-Nicolle I, Ly S, Nouhin J, et al. (2012) High Frequency of Advanced Hepatic Disease among HIV/HCV Co-Infected Patients in Cambodia: The HEPACAM Study (ANRS 12267) J AIDS Clinic Res 3: 1-7.
23. van Griensven J, Thai S (2011) Predictors of immune recovery and the association with late mortality while on antiretroviral treatment in Cambodia. Trans R Soc Trop Med Hyg 105: 694-703.
24. van der Helm J, Geskus R, Sabin C, Meyer L, Del Amo J, et al. (2013) Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology 144: 751-760 e752.
25. Chen TY, Ding EL, Seage Iii GR, Kim AY (2009) Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 49: 1605-1615.
26. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, Moschidis Z, Sypsa V, et al. (2009) Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 48: 1763-1771.
27. Matthews GV, Manzini P, Hu Z, Khabo P, Maja P, et al. (2011) Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. AIDS 25: 1727-1735.
28. Hoffmann CJ, Seaberg EC, Young S, Witt MD, D'Acunto K, et al. (2009) Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 23: 1881-1889.
29. Hepatitis B virus (HBV) and Hepatitis C Virus (HCV) Coinfection: Long-term immunological, virological and survival outcomes following cART (2013). 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention 30 June-3 July 2013, Kuala Lumpur, Malaysia.
30. Phan V, Thai S, Koole O, Menten J, Meheus F, et al. (2013) Validation of a clinical prediction score to target viral load testing in adults with suspected first-line treatment failure in resource-constrained settings. J Acquir Immune Defic Syndr 62: 509-516.
31. Lynen L, An S, Koole O, Thai S, Ros S, et al. (2009) An algorithm to optimize viral load testing in HIV-positive patients with suspected first-line antiretroviral therapy failure in Cambodia. J Acquir Immune Defic Syndr 52: 40-48.
32. Tuma P, Medrano J, Resino S, Vispo E, Madejon A, et al. (2010) Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. Antivir Ther 15: 881-886.
33. Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, et al. (2013) Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis. PLoS One 8: e68152.
34. Operskalski EA, Kovacs A (2011) HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 8: 12-22.
35. Ladep NG, Agaba PA, Agbaji O, Muazu A, Ugoagwu P, et al. (2013) Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort. World J Gastroenterol 19: 1602-1610.
36. Braitstein P, Zala C, Yip B, Brinkhof MW, Moore D, et al. (2006) Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program. J Infect Dis 193: 259-268. (Pubitemid 43113488)
37. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, et al. (2000) Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356: 1800-1805.
38. Miller MF, Haley C, Koziel MJ, Rowley CF (2005) Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis 41: 713-720. (Pubitemid 41170361)
39. Potter M, Odueyungbo A, Yang H, Saeed S, Klein MB (2010) Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. AIDS 24: 1857-1865.
40. Farias AA, Kremer LE, Allende L, Diaz Mdel P, Pisano MB, et al. (2013) Determinants of immunological and virological responses to antiretroviral therapy amongst HIV-infected adults in central Argentina: negative influence of hepatitis C infection. Trans R Soc Trop Med Hyg 107: 432-437.
41. Taye S, Lakew M (2013) Impact of hepatitis C virus co-infection on HIV patients before and after highly active antiretroviral therapy: an immunological and clinical chemistry observation, Addis Ababa, Ethiopia. BMC Immunol 14: 23.
42. Wandeler G, Gsponer T, Bihl F, Bernasconi E, Cavassini M, et al. (2013) Hepatitis B Virus Infection Is Associated With Impaired Immunological Recovery During Antiretroviral Therapy in the Swiss HIV Cohort Study. J Infect Dis 208: 1454-1458.
43. Peters L, Mocroft A, Soriano V, Rockstroh JK, Losso M, et al. (2009) Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. J Acquir Immune Defic Syndr 50: 457-463.
44. Yacisin K, Maida I, Rios MJ, Soriano V, Nunez M (2008) Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy. AIDS Res Hum Retroviruses 24: 935-940.
45. Antonello VS, Appel-da-Silva MC, Kliemann DA, Santos BR, Tovo CV (2013) Immune restoration in human immunodeficiency virus and hepatitis C virus coinfected patients after highly active antiretroviral therapy. Braz J Infect Dis.
46. Mbougua JB, Laurent C, Kouanfack C, Bourgeois A, Ciaffi L, et al. (2010) Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. BMC Public Health 10: 105.
47. Moore E, Beadsworth MB, Chaponda M, Mhango B, Faragher B, et al. (2010) Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection. J Infect 61: 155-163.
48. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, et al. (2005) Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 19: 593-601. (Pubitemid 40543982)
49. French AL, Evans CT, Agniel DM, Cohen MH, Peters M, et al. (2013) Microbial Translocation and Liver Disease Progression in Women Coinfected With HIV and Hepatitis C Virus. J Infect Dis.
50. Pinzone MR, Di Rosa M, Cacopardo B, Nunnari G (2012) HIV RNA suppression and immune restoration: can we do better? Clin Dev Immunol 2012: 515962.
51. Page EE, Nelson M, Kelleher P (2011) HIV and hepatitis C coinfection: pathogenesis and microbial translocation. Curr Opin HIV AIDS 6: 472-477.
52. Andrade BB, Hullsiek KH, Boulware DR, Rupert A, French MA, et al. (2013) Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses. J Infect Dis 207: 1379-1388.
53. Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, et al. (2003) Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 17: 2191-2199. (Pubitemid 37338892)
54. Chung RT, Evans SR, Yang Y, Theodore D, Valdez H, et al. (2002) Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 16: 1915-1923.
55. Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, et al. (2008) A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 48: 1062-1069.
56. Ford N, Kirby C, Singh K, Mills EJ, Cooke G, et al. (2012) Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. Bull World Health Organ 90: 540-550.
57. Maek ANW, Avihingsanon A, Ohata PJ (2012) Challenges in Providing Treatment and Care for Viral Hepatitis among Individuals Co-Infected with HIV in Resource-Limited Settings. AIDS Res Treat 2012: 948059.
58. Nguyen LH, Nguyen MH (2013) Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther 37: 921-936.
59. Liang TJ, Ghany MG (2013) Current and future therapies for hepatitis C virus infection. N Engl J Med 368: 1907-1917.
60. Ford N, Singh K, Cooke GS, Mills EJ, von Schoen-Angerer T, et al. (2012) Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis 54: 1465-1472.
61. Cachay ER, Hill L, Ballard C, Colwell B, Torriani F, et al. (2013) Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model. AIDS Res Ther 10: 9.